These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 10845833

  • 1. Protection of alpha(3) integrin-mediated podocyte shape by superoxide dismutase in the puromycin aminonucleoside nephrosis rat.
    Kojima K, Matsui K, Nagase M.
    Am J Kidney Dis; 2000 Jun; 35(6):1175-85. PubMed ID: 10845833
    [Abstract] [Full Text] [Related]

  • 2. Dipyridamole and dilazep suppress oxygen radicals in puromycin aminonucleoside nephrosis rats.
    Nakamura K, Kojima K, Arai T, Shirai M, Usutani S, Akimoto H, Masaoka H, Nagase M, Yamamoto M.
    Eur J Clin Invest; 1998 Nov; 28(11):877-83. PubMed ID: 9824428
    [Abstract] [Full Text] [Related]

  • 3. [Effects of human Cu, Zn-superoxide dismutase in aminonucleoside nephrosis--evaluation of the morphology and glomerular basement membrane anionic charge sites].
    Higuchi A.
    Nihon Jinzo Gakkai Shi; 1990 Jul; 32(7):767-75. PubMed ID: 2273594
    [Abstract] [Full Text] [Related]

  • 4. Tolvaptan, a selective oral vasopressin V2 receptor antagonist, ameliorates podocyte injury in puromycin aminonucleoside nephrotic rats.
    Okada T, Sakaguchi T, Hatamura I, Saji F, Negi S, Otani H, Muragaki Y, Kawachi H, Shigematsu T.
    Clin Exp Nephrol; 2009 Oct; 13(5):438-446. PubMed ID: 19452240
    [Abstract] [Full Text] [Related]

  • 5. Impact of cyclosporin on podocyte ZO-1 expression in puromycin aminonucleoside nephrosis rats.
    Kim BS, Park HC, Kang SW, Choi KH, Ha SK, Han DS, Lee HY.
    Yonsei Med J; 2005 Feb 28; 46(1):141-8. PubMed ID: 15744817
    [Abstract] [Full Text] [Related]

  • 6. Dynamics of absolute amount of nephrin in a single podocyte in puromycin aminonucleoside nephrosis rats calculated by quantitative glomerular proteomics approach with selected reaction monitoring mode.
    Kawakami H, Kamiie J, Yasuno K, Kobayashi R, Aihara N, Shirota K.
    Nephrol Dial Transplant; 2012 Apr 28; 27(4):1324-30. PubMed ID: 21862459
    [Abstract] [Full Text] [Related]

  • 7. Amelioration of antioxidant enzyme suppression and proteinuria in cyclosporin-treated puromycin nephrosis.
    Wang JS, Yang AH, Chen SM, Young TK, Chiang H, Liu HC.
    Nephron; 1993 Apr 28; 65(3):418-25. PubMed ID: 8289993
    [Abstract] [Full Text] [Related]

  • 8. Retinoids as a potential treatment for experimental puromycin-induced nephrosis.
    Moreno-Manzano V, Mampaso F, Sepúlveda-Muñoz JC, Alique M, Chen S, Ziyadeh FN, Iglesias-de la Cruz MC, Rodríguez J, Nieto E, Orellana JM, Reyes P, Arribas I, Xu Q, Kitamura M, Lucio Cazana FJ.
    Br J Pharmacol; 2003 Jun 28; 139(4):823-31. PubMed ID: 12813006
    [Abstract] [Full Text] [Related]

  • 9. Antioxidants protect podocyte foot processes in puromycin aminonucleoside-treated rats.
    Ricardo SD, Bertram JF, Ryan GB.
    J Am Soc Nephrol; 1994 Jun 28; 4(12):1974-86. PubMed ID: 7919151
    [Abstract] [Full Text] [Related]

  • 10. GLEPP1 receptor tyrosine phosphatase (Ptpro) in rat PAN nephrosis. A marker of acute podocyte injury.
    Kim YH, Goyal M, Wharram B, Wiggins J, Kershaw D, Wiggins R.
    Nephron; 2002 Apr 28; 90(4):471-6. PubMed ID: 11961407
    [Abstract] [Full Text] [Related]

  • 11. Puromycin aminonucleoside suppresses integrin expression in cultured glomerular epithelial cells.
    Krishnamurti U, Zhou B, Fan WW, Tsilibary E, Wayner E, Kim Y, Kashtan CE, Michael A.
    J Am Soc Nephrol; 2001 Apr 28; 12(4):758-766. PubMed ID: 11274237
    [Abstract] [Full Text] [Related]

  • 12. Protective effect of radical scavenger edaravone against puromycin nephrosis.
    Matsumura H, Ashida A, Hirano K, Nakakura H, Tamai H.
    Clin Nephrol; 2006 Dec 28; 66(6):405-10. PubMed ID: 17176911
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of puromycin-induced renal injury by a superoxide dismutase derivative with prolonged in vivo half-life.
    Nishimura Y, Nakayama M, Sato T, Tomita K, Inoue M.
    Nephron; 1995 Dec 28; 70(4):460-5. PubMed ID: 7477653
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of heparin-binding epidermal growth factor-like growth factor increases albuminuria in puromycin aminonucleoside nephrosis.
    Khong TF, Fraser S, Katerelos M, Paizis K, Hill PA, Power DA.
    Kidney Int; 2000 Sep 28; 58(3):1098-107. PubMed ID: 10972674
    [Abstract] [Full Text] [Related]

  • 15. Studies on antinephritic effect of TJ-8014, syo-saiko-to-kyo-shyokyo-ka-ouren-bukuryou (5): Effects on puromycin aminonucleoside nephrosis and its mechanisms.
    Hattori T, Ito M, Suzuki Y.
    Jpn J Pharmacol; 1991 Aug 28; 56(4):465-73. PubMed ID: 1744988
    [Abstract] [Full Text] [Related]

  • 16. Reduced podocyte expression of alpha3beta1 integrins and podocyte depletion in patients with primary focal segmental glomerulosclerosis and chronic PAN-treated rats.
    Chen CA, Hwang JC, Guh JY, Chang JM, Lai YH, Chen HC.
    J Lab Clin Med; 2006 Feb 28; 147(2):74-82. PubMed ID: 16459165
    [Abstract] [Full Text] [Related]

  • 17. Glucocorticoid activates glomerular antioxidant enzymes and protects glomeruli from oxidant injuries.
    Kawamura T, Yoshioka T, Bills T, Fogo A, Ichikawa I.
    Kidney Int; 1991 Aug 28; 40(2):291-301. PubMed ID: 1942778
    [Abstract] [Full Text] [Related]

  • 18. Altered expression of NDST-1 messenger RNA in puromycin aminonucleoside nephrosis.
    Nakayama K, Natori Y, Sato T, Kimura T, Sugiura A, Sato H, Saito T, Ito S, Natori Y.
    J Lab Clin Med; 2004 Feb 28; 143(2):106-14. PubMed ID: 14966466
    [Abstract] [Full Text] [Related]

  • 19. Reactive oxygen species and antioxidant defense in puromycin aminonucleoside glomerulopathy.
    Gwinner W, Landmesser U, Brandes RP, Kubat B, Plasger J, Eberhard O, Koch KM, Olbricht CJ.
    J Am Soc Nephrol; 1997 Nov 28; 8(11):1722-31. PubMed ID: 9355075
    [Abstract] [Full Text] [Related]

  • 20. Key molecular events in puromycin aminonucleoside nephrosis rats.
    Guan N, Ding J, Deng J, Zhang J, Yang J.
    Pathol Int; 2004 Sep 28; 54(9):703-11. PubMed ID: 15363039
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.